We are live on ! Find out more
TRIL

Trillium Therapeutics Inc.
TRIL

Delisted

TRIL was delisted on the 16th of November, 2021.

Back to rankings

14 hedge funds and large institutions have $19M invested in Trillium Therapeutics Inc. in 2015 Q1 according to their latest regulatory filings, with 11 funds opening new positions, increasing their positions, 2 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

456% more capital invested

Capital invested by funds: $3.42M → $19M (+$15.6M)

120% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 5

75% more funds holding

Funds holding: 8 → 14 (+6)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
14
Holders Change
+6
Holders Change %
+75%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
–
Reduced
2
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
+$3.33M
2
ACA
Avoro Capital Advisors
New York
+$2.37M
3
SFM
Sphera Funds Management
Israel
+$1.4M
4
PCA
Private Capital Advisors
Connecticut
+$1.24M
5
SIM
Spark Investment Management
New York
+$541K

Top Sellers

Rank Fund Capital Flow
1
OM
Opaleye Management
Massachusetts
-$1.08M
2
KPF
K2 Principal Fund
Ontario, Canada
-$178K
3
ACP
Acuta Capital Partners
California
-$171K
4
TDC
Thompson Davis & Co
Virginia
-$45K
5
FMA
FNY Managed Accounts
New York
-$13.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
OM
1
Opaleye Management
Massachusetts
$5.26M -$1.08M -73,333 -22%
DM
2
Deerfield Management
New York
$4.57M +$3.33M +226,064 New
ACA
3
Avoro Capital Advisors
New York
$3.23M +$2.37M +160,697 New
SFM
4
Sphera Funds Management
Israel
$1.92M +$1.4M +95,000 New
PCA
5
Private Capital Advisors
Connecticut
$1.7M +$1.24M +83,820 New
SIM
6
Spark Investment Management
New York
$745K +$541K +36,700 New
BIM
7
Bogle Investment Management
Massachusetts
$589K +$430K +29,121 New
MIM
8
Monashee Investment Management
Massachusetts
$506K +$369K +25,000 New
ARTA
9
A.R.T. Advisors
New York
$313K +$228K +15,480 New
Deutsche Bank
10
Deutsche Bank
Germany
$129K +$94.4K +6,400 New
TRCT
11
Tower Research Capital (TRC)
New York
$31K -$6.37K -432 -26%
Morgan Stanley
12
Morgan Stanley
New York
$25K +$18.4K +1,250 New
EWM
13
Edge Wealth Management
New York
$10K +$7.38K +500 New
Royal Bank of Canada
14
Royal Bank of Canada
Ontario, Canada
$1K – – –
KPF
15
K2 Principal Fund
Ontario, Canada
– -$178K -19,783 Closed
ACP
16
Acuta Capital Partners
California
– -$171K -19,000 Closed
TDC
17
Thompson Davis & Co
Virginia
– -$45K -5,000 Closed
FMA
18
FNY Managed Accounts
New York
– -$13.5K -1,500 Closed

TRIL Hedge Fund Activity: Q1 2015 in Review

14 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q1 2015, worth a combined $19M — up 456% from $3.42M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new TRIL positions and 5 closed out — a net gain of 6 holders — while 0 added to existing stakes and 2 trimmed.

The largest buyer was Deerfield Management, opening a new position worth an estimated $3.33M. The largest seller was Opaleye Management, cutting an estimated $1.08M.

  • 14 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q1 2015, up from 8 in Q4 2014.
  • Funds reported $19M of Trillium Therapeutics Inc. stock for Q1 2015, up 456% quarter-over-quarter.
  • 11 funds opened new Trillium Therapeutics Inc. positions in Q1 2015 and 5 closed out, a net change of +6 holders.
  • The largest Trillium Therapeutics Inc. buyer in Q1 2015 was Deerfield Management, an estimated $3.33M added.
  • The largest Trillium Therapeutics Inc. seller in Q1 2015 was Opaleye Management, an estimated $1.08M sold.

Based on aggregated 13F filings for Q1 2015.